Kezar COO Mark Schiller cashes out 2,739 shares at $6.96 each as Aurinia merger closes

Context Kezar Life Sciences (NASDAQ: KZR) completed its merger with Aurinia Pharma U.S., Inc. on May 11, 2026. The merger required all Kezar shareholders to tender shares in a cash offer, with each share also receiving a CVR that could pay additional cash if future milestones are met. Executives, including the chief operating officer, were subject to the same terms.

Key Facts - Schiller tendered exactly 2,739 common shares into the merger tender offer. - Each share generated $6.955 in cash, the same amount paid to all shareholders. - In addition to cash, Schiller received one CVR per share; the CVR is non‑tradable and only pays out if specific performance targets are achieved under a separate agreement. - All of Schiller’s employee stock options were automatically cancelled or converted at the merger’s effective time, meaning he holds no Kezar stock or options after the transaction. - The disposition involved no additional cash consideration beyond the per‑share payment; the options were removed without separate compensation.

What It Means Schiller’s exit reflects the broader equity reset that the merger imposed on Kezar’s management. By converting or canceling all outstanding options, the merger eliminated any lingering incentive‑based claims on the combined company. The cash payout of $6.955 per share aligns with the market‑determined offer price, while the CVR provides a potential upside tied to Aurinia’s post‑merger performance. Investors should monitor the CVR milestone schedule, as any payouts could affect Aurinia’s cash flow and shareholder returns.

Looking Ahead The next focus will be the achievement of CVR milestones and how Aurinia integrates Kezar’s pipeline, which will shape future cash distributions to former Kezar shareholders like Schiller.